CoChat

Oxidative Stress: The Lead or Supporting Actor in the Pathogenesis of Diabetic Complications

Kuroki, Tatsuya, Isshiki, Keiji, King, George L. · 2003 · Journal of the American Society of Nephrology
Cited by 92

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Oxidative stress is increased in both diabetic and insulin resistance states and may contribute to the development of microvascular and cardiovascular diseases associated with both of these syndromes (1–4). In addition, oxidative stress has been suggested to cause abnormalities of insulin secretion and actions (5,6). The increases in oxidative stress is probably due to the abnormal metabolic milieu such as hyperglycemia, dyslipidemia, and elevated free fatty acids (FFA), which commonly occur in patients who have diabetes and less-than-perfect glycemic control and in insulin-resistant state (7–10). There are a great deal of evidence that oxidant productions are increased in vascular cells exposed to elevated levels of glucose and in various cardiovascular tissues derived from diabetic and insulin-resistant states. However, controversy exists as to the role of oxidative stress in the pathogenesis of diabetic microvascular and cardiovascular complications (11). In this article, we briefly provide an overview of the following questions: (1) Is oxidant stress increased in diabetic and insulin-resistant states? (2) What mechanisms is hyperglycemia using to produce the increases in oxidants? (3) Are the oxidants induced by diabetes involved in the specific vascular pathologies observed in clinical diabetes? (4) Can antioxidants ameliorate diabetic complications? For the first question, there is a wealth of reports that many protein, lipid, and DNA markers of oxidative stress are increased in cultured vascular cells exposed to high glucose levels and vascular tissues from animals and patients with diabetes. In cultured vascular cells, elevating glucose levels in the media has been shown to increase oxidant production including gluco-oxidants, glycated compounds, oxidized LDL, superoxidants, and nitrotyrosine (7,12–15). Similarly, elevated levels of isoprostanes, 8-hydroxydeoxyguanosine, and lipid peroxides have been reported in diabetic animals and in patients with diabetes (14–17). Although numerous reports have substantiated that oxidant productions are increased in diabetes, clinical evidence for tissue damage as results of oxidative stress has not been clearly demonstrated because both plasma and cells contain a large reserve of antioxidants. In fact, the levels of the various antioxidants in the plasma and cells have not consistently been shown to be decreased in the diabetic states (18–20). Nevertheless, substantial evidence exists that diabetes and insulin resistance are states of increased oxidative stress, and the production of oxidants are significantly increased. Increases in oxidant production, observed in diabetes and insulin-resistant states, are the products of metabolisms of hyperglycemia, FFA, and other metabolites (2,8–10), which are the results of insulin deficiency and resistance. For hyperglycemia, increases in oxidant productions are due to multiple processes. Glucose can undergo nonenzymatic reactions forming gluco-oxidants and glycated products, which can be oxidants (20,21). Metabolisms of the excessive intracellular glucose can occur by several processes such as aldose reductase, mitochondrial oxidative phosphorylation, activation of oxidases, and alteration of NADPH/NADP ratios (7,22–24). Among these possibilities, recent focus has been on mitochondrial metabolism and activation of NADPH oxidases (7,24). Suggestions have been made that most glucose-induced oxidants are derived from glycolysis and mitochondrial oxidative phosphorylation with the productions of superoxide (7). In addition, byproducts of this process will cause the activation of signaling cascades such as activation of protein kinase C (PKC), hexosamine productions, increase flux via aldose reductase (AR), and glycated products. However, other authors have reported that the metabolism of high glucose levels can activate NADPH oxidase in the vascular cells independent of mitochondrial metabolisms (24). One mechanism that can increase NADPH oxidase activity is the activation of PKC, which is elevated by glucose-induced elevation of diacylglycerol (DAG) via de novo synthesis pathway (24). Thus, it is very likely that hyperglycemia is increasing oxidant production by multiple pathways rather than a single dominant route. This is an important distinction because it is much simpler to design therapeutic agents for one target than for multiple pathways. Besides glucose, elevation of FFA, which is present in both diabetic and insulin-resistant states, also can increase oxidant productions because the metabolism of FFA is dependent on β-hydroxylation, acetyl-CoA, and uncouple mitochondrial oxidative phosphorylation (8–10,25,26). In fact, recent reports have demonstrated that increases in malondialdehyde levels and NF-kB expression can be detected in insulin-resistant states without hyperglycemia not only in vascular tissues but also in muscle and adipose tissues (10,27). In addition, FFA infusion can reduce the levels of glutathione

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.asn.0000077405.07888.07

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 92

Metadata

Authors
Kuroki, T., Isshiki, K., & King, G. L.
Venue
Journal of the American Society of Nephrology
Published
2003-08
Volume
14
Issue
suppl_3
Pages
S216-S220
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2122733445
Cited by
92
References
8
FWCI
3.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oxidative Stress: The Lead or Supporting Actor in the Pathogenesis of Diabetic Complications. https://app.cochat.ai/papers/10.1097/01.asn.0000077405.07888.07
The paper
Kuroki, T., Isshiki, K., & King, G. L. (2003). Oxidative Stress: The Lead or Supporting Actor in the Pathogenesis of Diabetic Complications. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000077405.07888.07

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.